2009/03/01 by M. Marre, J. Shaw, M. Brändle +6
paper · doi:10.1111/j.1464-5491.2009.02666.x
Abstract Aim To compare the effects of combining liraglutide (0.6, 1.2 or 1.8 mg/day) or rosiglitazone 4 mg/day (all n ≥ 228) or placebo ( n = 114) with glimepiride (2–4 mg/day) on glycaemic control, body weight and safety in Type 2 diabetes. Methods In total, 1041 adults (mean ± sd ), age 56 ± 10 years, weight 82 ± 17 kg and glycated haemoglobin (HbA 1c ) 8.4 ± 1.0% at 116 sites in 21 countries were stratified based on previous oral glucose‐lowering mono : combination therapies (30 : 70%) to participate in a five‐arm, 26‐week, double‐dummy, randomized study. Results Liraglutide (1.2 or 1.8 mg) produced greater reductions in HbA 1c from baseline, (−1.1%, baseline 8.5%) compared with placebo (+0.2%, P P P P P P P Conclusions Liraglutide added to glimepiride was well tolerated and provided improved glycaemic control and favourable weight profile.